Sensitization of human ovarian tumor cells by subtoxic CDDP to anti- Fas antibody-mediated cytotoxicity and apoptosis

Gynecologic Oncology

Volumn 62, Issue 2, 1996, Pages 282-291

  Uslu, Ruchan ^a   Jewett, Anahid ^a   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYLATED HYDROXYANISOLE; CISPLATIN; DNA FRAGMENT; FAS ANTIGEN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PLOIDY; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

EID: 0030220139     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0228     Document Type: Article

References (43)

1. 1. Feinberg, B., Kurzurock, R., Talpaz, M., Blick, M., Saks, S., and Gutterman, J. U. Phase 1 trial of intravenously administered recombinant tumor necrosis factor-alpha in cancer patients, J. Clin. Oncol. 6, 1328-1332 (1992).
2. 2. Rosenberg, S. A. The immunotherapy and gene therapy of cancer, J. Clin. Oncol. 10, 180-199 (1992).
3. 3. Brinkmann, U., and Pastan, I. Immunotoxins against cancer, Biochem. Biophys. Acta 1198, 27-45 (1994).
4. 4. Schmidt-Wolf, G., and Schmidt-Wolf, I. G. Human cancer and gene therapy, Ann. Hematol. 69, 273-279 (1994).
5. 5. Safrit, J., Tsuchitani, T., Zighelboim, J., and Bonavida, B. Hierarchy of sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs, and toxins, Cancer Immunol. Immunother. 34, 321-328 (1992).
6. 6. Morimoto, H., Yonehara, S., and Bonavida, B. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins, Cancer Res. 53, 2591-2596 (1993).
7. 7. Krosnick, J. A., Mule, J. J., McIntosh, J. K., and Rosenberg, S. A. Augmentation of antitumor efficacy by the combination of tumor necrosis factor and chemotherapeutic agents in vivo, Cancer Res. 49, 3729-3733 (1989).
8. 8. Mizutani, Y., and Bonavida, B. Overcoming cis-diamminedichloroplatinum II resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum II and TNF-α, Cancer 72, 809-818 (1993).
9. 9. Mizutani, Y., and Bonavida, B. Overcoming TNF-α and CDDP resistance of a human ovarian cancer cell line (C30) by treatment with buthionine sulfoximine in combination with TNF-α and/or CDDP, Int. J. Oncol. 3, 229-235 (1993).
10. 10. Uslu, R., and Bonavida, B. Role of free radicals in the synergy achieved by treatment with both TNF-α and CDDP on human ovarian carcinoma cells, Cancer 77, 725-732 (1996).
11. 11. Hersh, E. M. Immunosupressive agents, in Antineoplastic and immunosupressive agents I (A. C. Sartorelli and D. G. Johns, Eds.), Springer-Verlag, New York, pp. 557-617 (1974).
12. 12. Ehrke, M. J., and Mihich, E. Immunoregulation by cancer chemotherapeutic agents, in The reticuloendothelial system: A comprehensive treatise (J. W. Hadder and A. Szentivanyi, Eds.), Plenum, New York, pp. 309-347 (1985).
13. 13. Montavani, A., Luini, W., Vecchi, A., and Spreafico, F. Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice, J. Natl. Cancer Inst. 61, 1255-1258 (1978).
14. 14. Berd, D., Mastrangelo, M., Engstrom, P., Paul, A., and Maguire, H. Augmentation of the human immune response by cyclophosphamide, Cancer Res. 42, 4862-4867 (1982).
15. 15. Rosenberg, B., Van Camp, L., Trosko, J. E., and Mansour, V. H. Platinum compounds: A new class of potent antitumor agents, Nature 222, 285-286 (1969).
16. 16. Loehrer, P. J., and Einhorn, L. H. Drugs five years later. Cisplatin, Ann. Intern. Med. 100, 704-713 (1984).
17. 17. Pascoe, J. M., and Roberts, J. J. Interaction between mammalian cell DNA and inorganic platinum compounds I. DNA interstrand cross-linking and cytotoxic properties of platinum II compounds, Biochem. Pharmacol. 23, 1345-1357 (1974).
18. 18. Taylor, D. M., Tew, K. D., and Jones, J. D. Effects of cis-dichlorodiammineplatinum (II) on DNA synthesis in kidney and other tissues of normal and tumor-bearing rats, Eur. J. Cancer 12, 249-254 (1976).
19. 19. Hannemann, J., and Baumann, K. Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney kortex: Different effect of antioxidants and radical scavengers, Toxicology 51, 119-132.
20. 20. Masuda, H., Tanaka, T., and Takahama, U. Cisplatin generates superoxide anion by intercalation with DNA in a cell free system, Biochem. Biophys. Res. Commun. 203, 1175-1180 (1994).
21. 21. Uslu, R., and Bonavida, B. Free radicals dependent and independent pathways of CDDP-mediated cytotoxicity and apoptosis in ovarian tumor cell lines, Int. J. Oncol. 6, 1003-1009 (1995).
22. 22. Kleinerman, E. S., Zwelling, L. A., and Mushmore, A. V. Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum (II), Cancer Res. 40, 3099-3102 (1980).
23. 23. Lichenstein, A. K., and Pende, D. Enhancement of natural killer cytotoxicity by cis-diamminedichloroplatinum (II) in vivo and in vitro, Cancer Res. 46, 639-644 (1985).
24. 24. Sohdi, A., Pai, K., Singh, R. K., and Singh, S. M. Activation of human natural killer cells and monocytes with cisplatin in vitro, Int. J. Immunopharmacol. 12, 893-898 (1990).
25. 25. Mizutani, Y., Bonavida, B., Nio, Y., and Yoshida, O. Enhanced susceptibility of CDDP-treateated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells, Cancer 71, 1313-1321.
26. 26. Gan, X. H., Jewett, A., and Bonavida, B. Activation of human peripheral blood monocytes by CDDP: Enhanced tumoricidal activity and secretion of TNF-α, Nat. Immun. 11, 144-155 (1992).
27. 27. Nagata, S. Fas and Fas ligand: A death factor and its receptor. Adv. Immunol. 57, 129-144 (1994).
28. 28. Trauth, B. C., Klas, C., Peters, A. M. J., Matzky, S., Moller, P., Falk, W., Debatin, K. M., and Krammer, P. H. Monoclonal antibody-mediated tumor regression by induction of apoptosis, Science 245, 301-304 (1989).
29. 29. Yonehara, S., Ishii, A., and Yonehara, M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor, J. Exp. Med. 169, 1747-1756 (1989).
30. 30. Ogasawara, J., Watanabe-Fukanaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. Lethal effect of anti-Fas antibody in mice, Nature 364, 806-809 (1993).
31. 31. Krammer, P. H., Behrmann, I., Bier, V., Daniel, P., Dhein, J., Falk, M. H., Garcin, G., Klas, C., Knipping, E., Lucking-Famira, K. M., Matzku, S., Oehm, A., Richards, S., Trauth, B. C., Bornkamm, G. W., Falk, W., Moller, P., and Debatin, K. M. Apoptosis in APO-1 system, in Apoptosis: The molecular basis of cell death (L. D. Tomei and F. O. Cope, Eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 87-99 (1991).
32. 32. Watanabe-Fukanaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., and Nagata, S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis, Nature (London) 356, 314-317 (1992).
33. 33. Suda, T., Takahashi, T., Golstein, P., and Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family, Cell 75, 1169-1178 (1993).
34. 2+-independent T cell-mediated cytotoxicity, J. Exp. Med. 177, 195-200 (1993).
35. 35. Kagi, D., Vignaux, F., Ledermann, B., Burki, K., Depraetere, V., Nagata, S., Hengartner, H., and Golstein, P. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity, Science 265, 528-530 (1994).
36. 36. Hanabuchi, S., Koyanagi, M., Kawasaki, A., Shinohara, N., Matsuzawa, A., Nishimura, Y., Kobayashi, Y., Yonehara, S., Yagita, H., and Okumura, K. Fas and its ligand in a general mechanism of T cell-mediated cytotoxicity, Proc. Natl. Acad. USA 91, 4930-4934 (1994).
37. 37. Arase, H., Arasi, N., and Saito, T. Fas-mediated cytotoxicity by freshly isolated natural killer cells, J. Exp. Med. 181, 1235-1238 (1995).
38. 38. Telford, W. G., King, L. E., and Fraker, P. J. Rapid quantation of apoptosis in pure and heterogenous cell populations using flow cytometry, J. Immunol. Methods 172, 1-16 (1994).
39. 39. Darzynkiewicz, Z., Bruno, S., Del Nino, G., Gorzycca, W., Hotz, M. A., Lassota, P., and Traganos, F. Features of apoptotic cells measured by flow cytometry, Cytometry 13, 795-808 (1992).
40. 40. Berenbaum, M. C. Criterion for analyzing interactions between biologically active agents, Adv. Cancer Res. 35, 269-290 (1981).
41. 41. Wong, G. H. W., Elwell, J. H., Oberly, L. W., and Goeddel, D. V. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor, Cell 58, 923-931 (1989).
42. 42. Clement, M. V., and Stamenkovic, I. Fas and tumor necrosis factor receptor-mediated cell death: Similarities and distinctions, J. Exp. Med. 180, 557-567 (1994).
43. 43. Schulze-Osthoff, K., Walczak, H., Droge, W., and Krammer, P. H. Cell nucleus and DNA fragmentation are not required for apoptosis, J. Cell Biol. 127, 15-20 (1994).